UK Markets closed

Vaccine Contract Manufacturing Market Report 2022-2032

·7-min read

Forecasts by Process (Upstream Process, Downstream Process), by Downstream (Fill & Finish Operations, Analytical & QC Studies, Vaccine Packaging), by Upstream (Mammalian Expression Vaccine, Bacterial Expression Vaccine, Yeast Expression Vaccine, Baculovirus/Insect Expression Vaccine, Other), by Type (Subunit Vaccines, Live Attenuated Vaccines, Conjugate Vaccines, Inactivated Vaccines, Recombinant Vector Vaccines, Other), by Company Size (Small Manufacturers, Mid-sized Manufacturers, Large Manufacturers, Very Large Manufacturers), by Operation (Preclinical, Clinical, Commercial, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

New York, May 12, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Vaccine Contract Manufacturing Market Report 2022-2032" -

The Vaccine Contract Manufacturing Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such As Reduced Market Time, Infrastructure Cost Benefits, And Operational Benefits Are Driving The Market Growth

Some of the major forces propelling the global vaccine contract manufacturing market include reduced market time, infrastructure cost, and operational benefits. Furthermore, technical advancements such as the development of new expression systems like GPEx and EB66 cell lines and cell culture medium platforms are expected to propel market growth. On the other hand, few large organizations consider outsourcing to be harmful due to the loss of strategic and management control. Considerable investments in facilities, equipment, and skilled labour in countries looking to grow or localise their supply are expected to impact contract services adoption positively. In addition, several low-resource countries lack the requisite equipment and experienced personnel to manufacture vaccines, leading them to create contracts with contract producers to meet market demand.

On the other hand, few large organizations see outsourcing as a concern since it results in a loss of strategic and management control. As a result, big pharmaceutical companies prefer to maintain their manufacturing in-house. This aspect is predicted to hinder global acceptance of contract services over the forecast period.

Logistical And Administrative Challenges

Local governments will need a robust data infrastructure to identify eligible persons by priority group, make invites, organise transportation for elderly and disabled patients, and recall individuals to obtain second doses of particular vaccines. Several of the most promising vaccine ideas necessitate ultra-cold chains and have a short shelf life once extracted from storage. BioNTech and Pfizer’s mRNA vaccines, for example, must be administered within five days of leaving ultra-low temperature settings (–70°C); Moderna’s mRNA vaccine has similar, if less stringent, restrictions. Strong coordination between central depots & local vaccinators would be necessary to ensure the timely & effective delivery of mRNA vaccine batches to regions without freezers.

What Are These Questions You Should Ask Before Buying A Market Research Report?
• How is the vaccine contract manufacturing market evolving?
• What is driving and restraining the vaccine contract manufacturing market?
• How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each vaccine contract manufacturing submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the vaccine contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implication of vaccine contract manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
• Where is the vaccine contract manufacturing market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path? C-suite?

You need to discover how this will impact the vaccine contract manufacturing market today, and over the next 10 years:
• Our 565-page report provides 377 tables and 379 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analyse of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the vaccine contract manufacturing market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising vaccine contract manufacturing prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.

Segments Covered in the Report

Process Outlook
• Upstream Process
– Mammalian Expression Vaccine
– Bacterial Expression Vaccine
– Yeast Expression Vaccine
– Baculovirus/Insect Expression Vaccine
– Other Upstream
• Downstream Process
– Fill & Finish Operations
– Analytical & QC Studies
– Vaccine Packaging

• Subunit Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Recombinant Vector Vaccines
• Other Vaccine Type

Company Size
• Small Manufacturers
• Mid-sized Manufacturers
• Large Manufacturers
• Very Large Manufacturers

• Preclinical
• Clinical
• Commercial
• Other Operations

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:

North America
• U.S.
• Canada
• Mexico

• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

• Brazil
• Turkey
• Saudi Arabia
• South Africa
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Vaccine Contract Manufacturing Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie Inc. (AbbVie)
• Bavarian Nordic A/S
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Emergent BioSolutions Inc.
• Eurofins Scientific SE
• FUJIFILM Holdings Corporation
• GlaxoSmithKline PLC
• Kemwell Biopharma
• Lonza Group AG (Lonza)
• Merck KGaA
• Pfizer Inc. (Pfizer)
• Richter-Helm BioLogics
• Samsung Biologics Co Ltd
• Sanofi SA
• Serum Institute of India
• Siegfried Holding AG
• Thermo Fisher Scientific Inc.
• Wacker Biotech B.V
• WuXi Biologics Cayman Inc

Overall world revenue for Vaccine Contract Manufacturing Market, 2022 to 2032 in terms of value the market will surpass US$2,676 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Vaccine Contract Manufacturing Market, 2022 to 2032 Market report helps you?

In summary, our 560+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Vaccine Contract Manufacturing Market, 2022 to 2032 Market, with forecasts for Process, upstream, downstream, type company size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 4 regional and 20 key national markets – See forecasts for the Vaccine Contract Manufacturing Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Vaccine Contract Manufacturing Market, 2022 to 2032 Market.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting